Immunovant (IMVT) fell 12% in pre-market trading after batoclimab failed to meet primary endpoints in Phase 3 thyroid eye disease trials. While the low-dose phase showed improvement, it wasn't enough to prevent the stock from hitting a four-month low. The company is now focusing on IMVT-1402 for autoimmune conditions like Graves' disease.